Phases, active trials: Phase 1: 46, Phase 1/2: 10, Phase 2: 29, Phase 2/3: 5, Phase 3: 94, Phase 4: 10, No phase listed: 68
Pfizer's clinical pipeline spans oncology, rare disease, infectious disease, and inflammation. In oncology, Ibrance (palbociclib) remains a mainstay of HR+ breast cancer treatment with ongoing combination trials, while Lorbrena (lorlatinib) anchors the ALK-positive NSCLC franchise. The 2023 acquisition of Seagen brought Padcev (enfortumab vedotin) and Tukysa (tucatinib), expanding Pfizer's ADC and HER2 capabilities significantly. In rare disease, Pfizer's hemophilia gene therapy program and pipeline in Pompe disease and Duchenne MD represent major development investments. Their mRNA platform, validated by the COVID vaccine, is being applied to influenza, RSV, and oncology vaccine targets.
- Oncology (breast, NSCLC, urothelial, hematology)
- Rare disease / gene therapy
- Inflammation / immunology
- Infectious disease / vaccines
- mRNA therapeutics
- Ibrance (palbociclib): CDK4/6 inhibitor, HR+ breast cancer
- Lorbrena (lorlatinib): ALK-positive NSCLC
- Padcev (enfortumab vedotin): urothelial ADC
- Tukysa (tucatinib): HER2+ breast/gastric/CRC
- Xtandi (enzalutamide): prostate cancer
- Braftovi (encorafenib): BRAF-mutant tumors
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With… NCT04557449 | Primary completion moved at least 3 years later Primary endpoint(s) modified | Recruiting |
30 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study to Learn About the Study Medicine Called Rimegepant in Women When Used… NCT06641466 | Nov 29, 2026 · Estimated | Phase 3 |
22 more on the Completions page. See the calendar →
Monitor the Pfizer pipeline daily
Get a daily digest when Pfizer registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Obesity | 14 |
| Breast Cancer | 12 |
| Atopic Dermatitis | 11 |
| Overweight and/or Obesity | 11 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Multiple Myeloma | 10 |
| Overweight | 10 |
| Healthy | 9 |
Pfizer's Seagen acquisition pipeline is actively generating new combination trials across Padcev, Tukysa, and tisotumab vedotin. Their Phase 3 program in urothelial cancer, HER2+ tumors, and cervical cancer is one of the fastest-growing competitive spaces in oncology.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Pfizer's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Pfizer may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Pfizer pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a… NCT07794748 | Active, Not Recruiting | Study completion moved earlier from Jun 7, 2027 to Apr 26, 2027 | 2026-11-13 |
| ATGAM General Investigation NCT06039020 | Active, Not Recruiting | Study completion pushed from Jan 22, 2027 to Mar 26, 2027 | 2026-11-13 |
| This is a Study to Learn About How the Combination of the Study Medicines… NCT06758401 | Recruiting | Trial sites expanded: 389 → 392 locations | 2026-11-13 |
| A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone… NCT06587035 | Recruiting | Primary completion pushed from Sep 21, 2026 to Sep 5, 2028 | 2026-11-13 |
| A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years… NCT06807268 | Active, Not Recruiting | Enrollment closed, study ongoing | 2026-11-13 |
Each trial page shows every change DataLookout has recorded for that trial.